Friend or Foe—Are Benign Lymphadenopathies Really Benign?
In recent years, we have witnessed major shifts in our understanding of several entities known as “benign lymphadenopathies.” Recognition of new pathogenetic aspects and their influence on the prognosis has changed our diagnostic and treatment approaches. This presentation focuses on important entities including Castleman disease, IgG4-related disease, and benign T- and B-cell proliferations. The discussion will emphasize the most recent recommendations that encompass the changes in the diagnostic work-up and the clinical significance of the rendered pathologic diagnosis.
